Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Rochester, MN
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Omaha, NE
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
New York, NY
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Durham, NC
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Columbus, OH
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Portland, OR
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Nashville, TN
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Houston, TX
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Seattle, WA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
mi
from
Vancouver,
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
mi
from
Vancouver,
Click here to add this to my saved trials
Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis
Validation of Endoscopic Ultrasound Criteria for Diagnosis of Chronic Pancreatitis Using Dual Secretin and Cholecystokinin Pancreatic Function Testing as Reference Standard
Status: Enrolling
Updated:  2/2/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis
Validation of Endoscopic Ultrasound Criteria for Diagnosis of Chronic Pancreatitis Using Dual Secretin and Cholecystokinin Pancreatic Function Testing as Reference Standard
Status: Enrolling
Updated: 2/2/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Orlando, FL
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia
Status: Enrolling
Updated:  2/4/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia
Status: Enrolling
Updated: 2/4/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Scripps Clinic
mi
from
La Jolla, CA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Loma Linda University Medical Center
mi
from
Loma Linda, CA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Cedar Sinai Medical Center
mi
from
Los Angeles, CA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Cedar Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Univeristy of California, San Diego
mi
from
San Diego, CA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Univeristy of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
California Pacific Medical Center
mi
from
San Francisco, CA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University of Florida
mi
from
Gainsville, FL
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University of Florida
mi
from
Gainsville, FL
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University of Miami
mi
from
Miami, FL
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University of Chicago
mi
from
Chicago, IL
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Loyola University Medical Cente
mi
from
Maywood, IL
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Loyola University Medical Cente
mi
from
Maywood, IL
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Indiana University
mi
from
Indianapolis, IN
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University of Louisville
mi
from
Louisville, KY
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Henry Ford Hospital
mi
from
Detroit, MI
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Rutgers New Jersey Medical School
mi
from
Newark, NJ
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Rutgers New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
North Shore University Hospital
mi
from
Manhasset, NY
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Mt. Sinai School of Medicine
mi
from
NYC, NY
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Mt. Sinai School of Medicine
mi
from
NYC, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
NYU Medical Center
mi
from
NYC, NY
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
NYU Medical Center
mi
from
NYC, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University of Cincinnati Physicians Company, LLC
mi
from
Cincinnati, OH
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University of Cincinnati Physicians Company, LLC
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Einstein Healthcare Network
mi
from
Philadelphia, PA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Einstein Healthcare Network
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Baylor All Saints Medical Center
mi
from
Forth Worth, TX
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Baylor All Saints Medical Center
mi
from
Forth Worth, TX
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Baylor College of Medicine
mi
from
Houston, TX
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Baylor St. Luke's Medical Center
mi
from
Houston, TX
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Baylor St. Luke's Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
UT Health Science Center - Houston
mi
from
Houston, TX
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
UT Health Science Center - Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
University Of Utah Hospital
mi
from
Salt Lake City, UT
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Bon Secours Mary Immaculate Hospital
mi
from
Newport News, VA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Bon Secours Mary Immaculate Hospital
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated:  2/4/2016
Bon Secours St. Mary's Hospital of Richmond, Inc.
mi
from
Richmond, VA
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Status: Enrolling
Updated: 2/4/2016
Bon Secours St. Mary's Hospital of Richmond, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Gastrointestinal Mucosal Findings in Patients Receiving Mycophenolic Acid (MPA) as Demonstrated by Small Bowel Capsule Endoscopy (SBCE)
Status: Enrolling
Updated:  2/5/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Gastrointestinal Mucosal Findings in Patients Receiving Mycophenolic Acid (MPA) as Demonstrated by Small Bowel Capsule Endoscopy (SBCE)
Status: Enrolling
Updated: 2/5/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety of Vitamin D Supplementation in Older Persons
Safety of Vitamin D Supplementation in the Elderly
Status: Enrolling
Updated:  2/5/2016
University of Miami
mi
from
Miami, FL
Safety of Vitamin D Supplementation in Older Persons
Safety of Vitamin D Supplementation in the Elderly
Status: Enrolling
Updated: 2/5/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children
Status: Enrolling
Updated:  2/8/2016
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children
Status: Enrolling
Updated: 2/8/2016
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Click here to add this to my saved trials
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
Status: Enrolling
Updated:  2/8/2016
University of Colorado Hospital, Denver Health Medical Center
mi
from
Aurora, CO
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
Status: Enrolling
Updated: 2/8/2016
University of Colorado Hospital, Denver Health Medical Center
mi
from
Aurora, CO
Click here to add this to my saved trials